AML risk stratification may be simplified integrating determination of MRD at the end of consolidation, with conventional cytogenetic/genetic classification. Two prognostically distinct groups can be identified: (1) low-risk, including good K-MRD⁻ and intermediate K-MRD⁻ patients; and (2) high-risk, including good K-MRD⁺, intermediate K-MRD⁺, poor-risk cytogenetics, and FLT3-ITD cases. The 2 groups stand for significantly different OS (A), RFS (B), and CIR (C) than those who remain MRD⁺ (P < .001 for all comparisons).